Price
111.41
-2%52W Range
Market Cap
₹810.92 Cr
Traded: ₹2.86 Cr (0.35%) 0.0x
Free Float: ₹119.04 Cr (2.40% of FF traded)
Volume · 60D trend
2.52 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | +41.0% | +34.0% | -- | -- | Decelerating |
| Sales | -- | -- | +33.0% | -- | +48.0% | Accelerating |
| Profit | -- | -- | +22.0% | -- | +28.0% | Accelerating |
| Return | -- | -- | -- | -- | -- | -- |
Quarterly Results
Sep 2025
Jun 2025
Mar 2025
Dec 2024
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales | 19 | 30 | 25 | 32 | 18 | 27 | 14 |
| Expenses | 17 | 18 | 18 | 18 | 13 | 18 | 9 |
| Operating Profit | 2 | 12 | 7 | 14 | 5 | 9 | 6 |
| OPM % | 12.5% | 40.1% | 26.8% | 43.4% | 29.0% | 32.4% | 39.3% |
| Other Income | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Depreciation | 1 | 1 | 0 | 1 | 1 | 0 | 1 |
| Profit Before Tax | 2 | 10 | 5 | 13 | 4 | 8 | 5 |
| Tax % | 27.8% | 19.8% | 27.0% | 26.6% | 24.0% | 21.0% | 27.7% |
| Net Profit | 2 | 8 | 4 | 9 | 3 | 6 | 3 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 0.2 | 1.1 | 0.6 | 1.5 | 0.5 | 1.1 | 0.6 |
| Sales Growth (YoY) | 9.1% | 12.7% | 70.0% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | 23.8% | -22.8% | 17.9% | -- | 86.7% | -- |
| OP Growth (YoY) | -52.8% | 39.6% | 15.9% | -- | -- | -- | -- |
| OP Growth (QoQ) | -80.0% | 85.5% | -52.4% | 167.4% | -40.9% | 54.1% | -- |
| Profit Growth (YoY) | -42.0% | 29.4% | 6.8% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | 9.5% | 7.3% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 94.9% | -61.4% | 45.7% | -- | 90.9% | -- |
| OP Margin | -- | 40.1% | 26.8% | 43.4% | -- | 32.4% | 39.3% |
| Net Margin | -- | 27.6% | 14.8% | 29.6% | -- | 24.0% | 23.6% |
| Material Cost % | 32.4% | 27.2% | 43.7% | 29.8% | 29.3% | 39.9% | 8.4% |
| Employee Cost % | 11.8% | 6.9% | 8.7% | 6.2% | 10.3% | 7.6% | 13.8% |
| P/S | 7.65 | 8.06 | -- | -- | -- | -- | -- |
| P/E | 31.74 | 29.11 | -- | -- | -- | -- | -- |
| P/B | 5.34 | 6.02 | 13.05 | -- | -- | -- | -- |
Exchange Filings
50Transcript of Earnings Call on Unaudited Standalone and Consolidated Financial Resullts for the quarter ended June 30, 2026.
Gaudium IVF and Women Health Limited has informed the Exchange about Audio recording of the Earnings Call on the Financial Results for the quarter ended June 30, 2026.
Newspaper publication of the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.
Revised Investor Presentation on the Financial Results of the Company for the quarter ended June 30, 2026
Investor Presentation on the Financial Results of the Company for the quarter ended June 30, 2026.
Monitoring Agency Report for the quarter ended June 30, 2026.
Press Release on the Unaudited Financial Results of the Compony for the quater ended June 30, 2026.
Intimation of Statement of Deviation & Variation of Funds for the quater ended June 30, 2026
Appointment of Secretarial Auditor of the Company for a term of 5 Years, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting of the Company.
Appointment of Internal Auditor of the Company for the Financial Year 2026-27.
Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026
Unaudited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2026
Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you ....
Gaudium IVF And Women Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve the Un-audited ....
Press Release- India''s First Listed IVF Company, Gaudium IVF, Unveils AI Powered Signature Labs, Kicking Off Planned 19 Centre Expansion
Intimation regarding commencement of commercial operations at Company''s new IVF Centre/Hub at South Extension, New Delhi
Compliance Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026
Gaudium IVF and Women Health Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Gaudium IVF and Women Health Limited has informed the Exchange about Corrigendum to the Financial Results submitted for the quarter and year ended March 31, 2026
Approval for setting up of Gaudium Women Hospital at Lucknow, Uttar Pradesh
Gaudium IVF and Women Health Limited has informed the Exchange about Schedule of meet
Press Release on Audited Financial Results for the quarter and year March 31, 2026
Investor Presentation on the Financial Results of the Company for the quarter and year ended March 31, 2026
Newspaper publication of the Audited Financial Results for the quarter and year ended March 31, 2026
Audio recording of Q4 & FY26 Earnings Conference Call
Standalone and Consolidated Audited Financial Results for the Quarter and Year ended March 31, 2026
Standalone and Consolidated Audited Financial Results for the Quarter and Year ended March 31, 2026
Intimation Under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Gaudium IVF And Women Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve the Audited Standalone ....
Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you ....
Monitoring Agency Report for quarter ended March 31, 2026
The Exchange has sought clarification from Gaudium IVF and Women Health Ltd on April 16, 2026 with reference to significant movement in price, in order to ensure that investors have latest ....
Clarification on Price Movement
Gaudium IVF and Women Health Limited has informed the Exchange regarding ''Change of Corporate Identification Number of the Company''
Compliance Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018
Gaudium IVF and Women Health Limited has updated the Exchange on the query received from BSE Limited vide its email dated April 07, 2026, seeking additional details for Corporate Announcement ....
Intimation Under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations'')
Intimation Under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 ("Listing Regulations")
Press Release
Pursuant to the provisions of the Code on Prohibition of Insider Trading of Gaudium IVF and Women Health Limited ("Company") and the SEBI PIT Regulations, 2015, as amended from time to ....
Pursuant to Regulation 47 of SEBI Listing Regulations, 2015, copies of newspaper publication of Unaudited Financial Results for the quater & nine months ended December 31, 2025 is attached herewith.
Press Release on the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025
Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2025
Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2025
Appointment of Internal Auditors of the Company for the Financial Year 2025-26 and appointment of Secretarial Auditors of the Company for the Financial Year 2025-26.
Gaudium IVF And Women Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/03/2026 ,inter alia, to consider and approve unaudited standalone ....
Intimation under Regulation 7(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, an intimation is attached herewith
Intimation under Regulation 8(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015, Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information ....
Intimation under Regulation 6(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, an intimation is attached herewith
Pursuant to the Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we request you to note that the Board of Directors have authorized Chairperson ....
Annual Reports
12025